Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects

Expert Review of Anticancer Therapy
Mariana BrandãoEvandro De Azambuja

Abstract

HER2-positive disease is an aggressive subtype of breast cancer that has been revolutionized by anti-HER2 directed therapies. Multiple drugs have been developed and are currently in clinical use, including trastuzumab, lapatinib, pertuzumab, T-DM1, and neratinib, alone or combined in 'dual HER2-blockade' regimens. Areas covered: A comprehensive literature review was performed regarding the current state and the future of combination regimens containing anti-HER2 agents, focusing on their efficacy, toxicity, and cost-effectiveness. Expert commentary: The combination of trastuzumab/pertuzumab is approved in all disease settings, while trastuzumab/neratinib is approved in the adjuvant setting and trastuzumab/lapatinib in metastatic disease. Meanwhile, as breast cancer biology and resistance mechanisms become clearer, combinations with drugs like PI3K/Akt/mTOR inhibitors, CDK4/6 inhibitors, anti-PD(L)1 antibodies, endocrine therapy, and new anti-HER2 agents (panHER and HER2 tyrosine kinase inhibitors, bispecific antibodies, anti-HER3 antibodies, and antibody-drug conjugates) are being extensively tested in clinical trials. More specific strategies for the 'triple-positive' (estrogen receptor-positive/HER2-positive) disease are also...Continue Reading

References

Mar 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gottfried E KonecnyMark D Pegram
Apr 13, 2011·Proceedings of the National Academy of Sciences of the United States of America·John StaggMark J Smyth
Dec 23, 2011·Molecular Cancer Therapeutics·Sauveur-Michel MairaCharles F Voliva
Apr 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valentina GuarneriPierfranco Conte
Jun 9, 2012·Nature·Anthony D BarnoskyAdam B Smith
Jun 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly L BlackwellJoyce O'Shaughnessy
Jul 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J CortésS M Swain
Sep 7, 2013·Oncotarget·Alexandra CanoniciAnthony Kong
Oct 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gail D Lewis PhillipsMark X Sliwkowski
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Apr 16, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHoward A Burris
Sep 19, 2014·World Journal of Gastrointestinal Oncology·Luis Gijón de la SantaLea Marie Klein
Jan 8, 2015·The New England Journal of Medicine·Sara M TolaneyEric P Winer
Feb 19, 2015·The New England Journal of Medicine·Sandra M SwainUNKNOWN CLEOPATRA Study Group
Apr 1, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Claus HanuschGunter von Minckwitz
Jul 19, 2015·The Breast : Official Journal of the European Society of Mastology·Sharon T Wilks
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter B Bach
Sep 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ben Y DurkeeKathleen C Horst
Nov 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martine Piccart-GebhartEdith A Perez
Mar 31, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kari B WisinskiGlenn Liu
May 4, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matteo ClavarezzaAndrea De Censi

❮ Previous
Next ❯

Citations

May 15, 2019·Expert Review of Anticancer Therapy·N KoteckiA Awada
Nov 15, 2019·International Journal of Cancer. Journal International Du Cancer·Matteo LambertiniUNKNOWN GIM2 investigators
Dec 17, 2019·British Journal of Cancer·Francis W HunterStephen M F Jamieson
Oct 23, 2019·Signal Transduction and Targeted Therapy·Jiani Wang, Binghe Xu
Oct 7, 2020·Cancers·Shailendra K GautamMohd Wasim Nasser
Sep 13, 2020·Signal Transduction and Targeted Therapy·Jiani Wang, Binghe Xu
Apr 2, 2021·International Journal of Pharmaceutics·Catarina OliveiraAlbino Martins

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Hematology/oncology and Stem Cell Therapy
George Orphanos, Panteleimon Kountourakis
American Society of Clinical Oncology Educational Book
Miguel Martín, Sara López-Tarruella
Revue médicale de Liège
Guy JerusalemP Coucke
The Breast : Official Journal of the European Society of Mastology
Santiago Escrivá-de-RomaníCristina Saura
© 2022 Meta ULC. All rights reserved